Journal of hypertension · 2025
Achieving blood pressure control with monotherapy: real-world evidence from office and home blood pressure measurements.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bezerra Rodrigo, Feitosa Audes D M, Guimarães-Neto Vanildo S, Barbosa Romero, Moura Fábio F, Mota-Gomes Marco A, Paiva Annelise M G, Barroso Weimar S, Miranda Roberto D, Barbosa Eduardo C D, Brandão Andréa A, Rodrigues Cibele I S, Bortolotto Luiz A, Lima-Filho José L, Sposito Andrei C, Nadruz Wilson
Аннотация
Despite guidelines discouragement, antihypertensive monotherapy (AH-mono) remains widely used. This study assessed AH-mono prevalence and blood pressure control rates based on office and home measurements (OBP/HBPM) using contemporary targets (<130/80 mmHg). Three distinct cohorts undergoing OBP/HBPM assessments between July 2018 and July 2024 were analyzed: cohort 1 ( n = 63 164) included treated patients with a single OBP/HBPM measurement; cohort 2 ( n = 5676) comprised treated patients with two OBP/HBPM assessments at different time points; and cohort 3 ( n = 974) involved individuals with OBP/HBPM measurements before and after initiating antihypertensive therapy. The prevalence of AH-mono was 42.7% in cohort 1, 36.6 and 32.4% in cohort 2, and 50.7% in cohort 3. Among those receiving AH-mono, OBP/HBPM control rates were 8.5% in cohort 1, 6.7 and 7.3% in Cohort 2, and 7.7% in cohort 3. These real-world findings highlight the persistent high prevalence of AH-mono despite its limited efficacy, with less than 10% of patients achieving blood pressure control.